Daily Stock Analysis, PTX, Pernix Therapeutics Holdings Inc, priceseries

Pernix Therapeutics Holdings Inc. Daily Stock Analysis
Stock Information
Open
0.22
Close
0.21
High
0.23
Low
0.20
Previous Close
0.08
Daily Price Gain
0.13
YTD High
2.20
YTD High Date
Feb 13, 2019
YTD Low
0.07
YTD Low Date
Mar 21, 2019
YTD Price Change
-0.22
YTD Gain
-51.88%
52 Week High
2.95
52 Week High Date
May 17, 2018
52 Week Low
0.07
52 Week Low Date
Mar 21, 2019
52 Week Price Change
-2.17
52 Week Gain
-91.30%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
2.28
Jan 19. 2017
2.88
9 Trading Days
26.27%
Link
LONG
Feb 22. 2017
2.74
Mar 29. 2017
3.42
25 Trading Days
24.82%
Link
LONG
Apr 21. 2017
3.71
May 15. 2017
5.53
16 Trading Days
49.12%
Link
LONG
Feb 26. 2018
2.51
Mar 9. 2018
2.79
9 Trading Days
11.21%
Link
Company Information
Stock Symbol
PTX
Exchange
NasdaqGM
Company URL
http://www.pernixtx.com
Company Phone
(862) 260-8457
CEO
John A. Sedor
Headquarters
New Jersey
Business Address
10 NORTH PARK PLACE, SUITE 201, MORRISTOWN, NJ 07960
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001024126
About

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. The company was founded on March 9, 2010 and is headquartered in The Woodlands, TX.

Description

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products. The company's products comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; and Khedezla, a prescription medication for major depressive disorder. Its products also include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro and Rezira for the relief of cough and nasal congestion; Vituz, a hydrocodone bitartrate and chlorpheniramine maleate combination oral solution for the treatment of cough and allergies associated with the common cold; and OMECLAMOX-PAK, a gastroenterology product. The company sells its products through its sales force and third-party sales organizations, as well as through its subsidiaries. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.